Maiden Forgings (543874)
CyclicalScore breakdown: P/E: 1/3 · ROCE: 0/2 · Growth: 0/2 · Dividend: 0/1
Key Financials
| Current Price | ₹103.69 |
| Market Cap | ₹147.36 Cr |
| P/E Ratio | 29.54 |
| ROCE | 11.35% |
| ROE | —% |
| Dividend Yield | 0% |
| Profit Growth | -48.15% |
| Debt/Equity | — |
| Sales Growth | 0.32% |
| 52-Week Range | ₹63.52 — ₹103.69 |
| Sector | Industrial Products |
Strengths
- Sales held nearly flat at 0.32% growth, showing some short-term stability.
- Latest quarter remains profitable with ₹2 Cr net profit on ₹109 Cr sales.
- ROCE of 11.35% suggests the existing capital base earns a moderate return.
- A quarterly revenue base of ₹109 Cr provides some scale despite the small market cap.
Concerns
- Profit growth is deeply negative at -48.15%, yet the stock trades at a P/E of 29.54.
- Piotroski F-Score of 4/9 points to weak financial health.
- Zero dividend yield means shareholders get no income support while waiting.
- Critical data like book value, debt/equity and promoter holding are missing, limiting a margin-of-safety check.
AI Analysis
Even at a glance, this is not the kind of business I would want to own forever. Maiden Forgings is an iron and steel products company, and in that world, the commodity cycle rules. The numbers tell me the company is barely earning anything in relation to the price. At ₹103.69, the market capitalisation is ₹147 crore. Trailing earnings, implied by a P/E of 29.54, are only about ₹5 crore. So I am paying nearly 30 times earnings for a business whose profits have fallen by 48.15% in the last year. That makes no investment sense unless you expect a sharp, sustainable recovery; Mr. Market seems to believe it, since the stock sits at the top of its 52-week range, but that is hope, not analysis. Looking at fundamentals, sales growth is a mere 0.32%, essentially stagnant. The latest quarter's net profit of ₹2 crore on sales of ₹109 crore gives a thin net margin of under 2%. The Piotroski F-Score of only 4 out of 9 reinforces my caution: this is a company with weak financial health, not a well-run gem. ROCE of 11.35% is not terrible, but for a cyclical commodity producer it is hardly a moat. There is no dividend, so the small shareholder gets no cash reward while waiting. There is also no book value, debt-equity, or promoter holding data, which itself is a red flag for a retail investor wanting transparency. A PEG ratio of 92.31 is meaningless except to say the market is paying an absurd price for almost no growth. This is a cyclical business at an unpleasant price. I would keep it on the watchlist, not in the portfolio.
Data from BSE/NSE filings. AI analysis is for educational purposes only — not investment advice. Scoring methodology · Disclaimer